Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

The rising BNPL star giving Afterpay a run for their money

  • In News
  • April 13, 2021
  • Samantha Freidin
The rising BNPL star giving Afterpay a run for their money

Zip Co (ASX: Z1P) is nipping at the heels of Australian BNPL leader Afterpay (ASX: APT), based on today’s announcement of their Q3 results. Despite the pandemic, Zip has managed to maintain momentum and deliver strong results across Australian, New Zealand, UK and US markets bolstering itself as one of the fastest growing BNPL leaders.

Q3 saw a record 12.4 million transactions (195% increase YoY) made on the platform which delivered quarterly transaction volume of $1.6 billion (up 114% YoY) and revenue of $114.4 million (up 80% YoY). The number of merchants on the platform has increased to 45.3k, a significant surge of 81% compared to last year.

Amongst these are a lineup of major retailers including Microsoft, Boohoo, JD Sports, JB HiFi, The Good Guys, L’Occitane, Boardriders and Adore Beauty.

An additional 1.6 million new app downloads globally bring the total amount of downloads to 7.6 million. In Australia alone there have been 230k new accounts registered.

Net bad debts for Australian receivables have reduced to 1.78% from 1.93%. Hardship requests and arrears are back to historically low levels, further affirming the Company’s ability to effectively manage risk.

Zip was trading at $3.80 before the pandemic and is currently trading at $9.10.

There is however, no sign of slowing down with this morning’s announcement detailing the Company’s plans and actions to date to branch into new global markets. During Q3 they’ve begun a soft launch into Canada and agreed on terms for investment into South East Asia through leading Philippines BNPL company, TendoPay.

The Company has also invested in Twisto, a BNPL player in Eastern Europe. BNPL is clearly a global phenomenon that Zip is poised to cash in on.

Zip is proving that their product can keep up with the likes of Afterpay by capitalising on the aversion to traditional credit cards and an affinity for mobile first operational systems. The Company’s Managing Director and CEO Larry Diamond is optimistic that Zip will “become the first payment choice everywhere, every day”.

With share prices more than doubling over the last 18 months, record transaction volumes, revenue and customer growth, this could be a very real possibility in the near future.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.